Global Laparoscopic Power Morcellators Market - 2021-2028
|出版日期||內容資訊||英文 180 Pages
|腹腔鏡下電動粉碎器的全球市場 (2021年∼2028年) Global Laparoscopic Power Morcellators Market - 2021-2028|
|出版日期: 2021年06月14日||內容資訊: 英文 180 Pages||
The global laparoscopic power morcellators market size was valued US$ XX billion in 2019 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).
Laparoscopic power morcellators are Class II medical devices used as a surgical technique to decrease the size of the uterus or myomas by making small pieces to enable the tissues to be removed through small incisions (typically 2 cm long or less).
Simple Approaches to Laparoscopic Power Morcellators is expected to drive the growth of the market.
According to the Journal, for women undergoing hysterectomy for mild disease, the American College of Obstetricians and Gynecologists recommends a minimally invasive approach. If the uterus is too big to be removed entirely through the vagina, morcellation is required to complete a vaginal hysterectomy. Moreover, the alternative to morcellation is to remove the uterus intact through an abdominal incision (abdominal hysterectomy). Similarly, removal of uterine myomas at the time of myomectomy without morcellation necessitates an abdominal incision.
In addition to using an abdominal procedure for hysterectomy, other alternative techniques to avoid the risks of power morcellation have been introduced, including hand-assisted morcellation through a mini-laparotomy and vaginal manual morcellation. Hence, adopting simple approaches to laparoscopic power morcellators is expected to drive the growth of the market.
Rising Prevalence For Uterine Fibroid Patients is expected to drive the growth of the market.
There is an increase in the prevalence of uterine fibroids globally, as it leads to abnormal uterine bleeding, amenorrhea, dysmenorrhea (painful and heavy menstrual periods), and pelvic or abdominal pressure. Moreover, it is estimated that not all women with uterine fibroids have symptoms, and around 50 to 75% of cases remain asymptomatic and usually remain untreated. Therefore, it is estimated that around 77% of women of childbearing age could face uterine fibroids.
According to an NCBI study report, around 30,000 myomectomies are performed periodically for leiomyomata (fibroids). The prevalence of uterine fibroids increases by women's age and may happen in over 30% of women aged between 40 to 60 years. Hence, from the above statements, the increase in the prevalence of uterine fibroids is expected to drive the market's growth.
Side Effects Associated with the laparoscopic power morcellators during myomectomy treatment are expected to hamper the market's growth.
According to the medical journal (11th June 2019), myomectomy is a surgical procedure to remove uterine fibroids called leiomyomas. These primary noncancerous growths appear in the uterus. Moreover, uterine fibroids usually develop during childbearing years, but they can occur at any age. Myomectomy has a low complication rate, but the procedure still poses a different set of challenges and risks, including excessive blood loss, Scar tissue, Pregnancy or childbirth complications, a rare chance of hysterectomy, and others. Additionally, in 2014, the Food and Drug Administration (FDA) cautioned against using a laparoscopic power morcellator for most women undergoing myomectomy. Hence, side effects associated with the laparoscopic power of morcellators during myomectomy treatment are expected to hamper the market's growth.
COVID-19 Impact Analysis
COVID-19 has moderately impacted the laparoscopic power morcellators market. Many hospitals are held to closing outpatient facilities in the hospital to restrict the spread of the disease and show the initial response for the treatment of COVID-19 patients. Moreover, cancellation of many surgeries, including hysterectomy/myomectomy. Thus, it has limited the usage of surgical devices in hospitals for a short-term period.
According to the European Society for Gynecological Endoscopy, the American Association of Gynecologic Laparoscopists has issued guidelines for performing non-invasive surgery in emergency cases. Additionally, it is expected that the market for laparoscopic power morcellators will undergo impetus during the forecast period and continue to witness an abundant growth rate after the end of the pandemic.
Power Morcellator segment is expected to hold largest share in this market segment
Power morcellators accounted for the largest market share in 2020 because of the faster recovery time associated with surgeries done with power morcellators and the rise in the patient pool for hysterectomy procedures. Moreover, small clumps of cancerous tissues left behind in the abdominal cavity after using power morcellators, resulting in cancer spreading to otherwise healthy tissues. For instance, according to the regulatory affairs professionals society, on 04 January 2021, FDA added that there must be a text of sample warning, to be bounded within a black box, stating a warning that, Uterine tissue may hold unsuspected cancer, and the use of laparoscopic power morcellators while fibroid surgery may spread cancer and decrease the life time of the patients. Moreover, it also stated that this information should be shared with patients when considering surgery using these devices. This factor is expected to hamper the growth of the power morcellators segment during the forecast period. Hence, from the above statements, power morcellators hold the largest market.
Hysterectomy segmentis expected to hold largest share in this market segment
The hysterectomy segment accounted for the largest revenue share in the laparoscopic power morcellators market in 2020. According to the medical journal published by Mayo Clinic on 25th February 2019, Vaginal hysterectomy is conducted to treat various gynecological problems, including fibroids, Endometriosis, Adenomyosis, Gynecological cancer, Uterine prolapse, Abnormal uterine bleeding and others. Moreover, it involves a shorter time in the hospital, lower cost and faster recovery than an abdominal hysterectomy. However, pregnancy is impossible after this procedure. For instance, as per the Journal of Obstetrics and Gynecology Canada (JOCG), 2nd September 2019, over 41,000 hysterectomies are performed annually in Canada. Hence, increasing hysterectomy surgeries is expected to impact the growth of the market positively. 11th June 2019
North America region holds the largest market share of global laparoscopic power morcellators market
North America has accounted for the largest revenue share in 2020. It was increasing gynecological surgical procedures, with well-established healthcare infrastructure and the increasing number of hospital visits. Moreover, rising government initiatives, the vast availability of advanced medical equipment and services, and a well-aware patient population are expected to increase the region's demand for laparoscopic power morcellators.
According to the Journal, In February 2020, the FDA released a renewed Safety Communication recommending that laparoscopic power morcellation for myomectomy or hysterectomy should be performed only with a tissue containment system legitimately marketed in the United States for use during laparoscopic power morcellation and is cooperative with only specifically designated laparoscopic power morcellators. Additionally, the FDA's February 2020 guidance stated that laparoscopic power morcellators for the removal of uterine tissue containing suspected leiomyomas should not be used in patients who are postmenopausal or older than 50 years, or "candidates for removal of tissue (en bloc) through the vagina or via a mini-laparotomy incision." Thus, considering the abovementioned factors, the market is likely to register significant growth over the forecast period.
The global laparoscopic power morcellatorsmarket is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market Medtronic, Karl Storz GmbH , Richard Wolf GmbH, LiNA Medical, Lumenis(Boston Scientific Corporation), Nouvag AG, Olympus Corporation, RUDOLF Medical GmbH, TongluWanhe Medical Instrument Co., Ltd., Zhejiang Geyi Medical Instrument Co., Ltd., and Hangzhou Euprun Medical Instrument Co., Ltd. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally.
Key Companies to Watch
LiNA Medical Company was founded by Niels Kornerup in 1977, initially designing and manufacturing ECG Electrodes. Moreover, it can focus on niche surgical specialties in developing innovative and simple devices for minimally invasive gynecology. Additionally, the company is into electro-surgery and laparoscopic surgery, including the launch of LiNAPowerBladeTM. It is dedicated to the continued development of innovative gynecological products that improve the quality of women's lives around the globe.
In LiNA Medical Company, the launch of LiNALoopTM catalyst is the company's strong focus on minimally invasive gynecology. Moreover, working closely with healthcare professionals has enabled the company to launch a range of successful gynecological products, including the LiNAXciseTM, LiNALibrataTM and LiNAOperaScopeTM.
In May 2020, Minerva Surgical received the Intrauterine Health products segment from Boston Scientific Corporation. The products include Symphion Tissue Removal System, Resect Tissue Resection Device, and the Genesys HTA System used to treat irregular uterine bleeding and other related disorders.
The global laparoscopic power morcellators market report would provide an access to an approx. 42 market data table, 31 figures and 200pages.
Global Laparoscopic Power Morcellators Market - By Product
Global Laparoscopic Power Morcellators Market - By Application
Global Laparoscopic Power Morcellators Market - By End use
Global Laparoscopic Power Morcellators Market - By Region
LIST NOT EXHAUSTIVE